Navigation Links
InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance

sting supply agreement with Boehringer Ingelheim Austria for the commercial and clinical supply of Actimmune.

Fourth Quarter and Recent Business Highlights

-- Pirfenidone: On November 26, InterMune announced that it had entered

into agreements with Marnac, Inc. and with co-licensor KDL GmbH that

will eliminate future royalty and milestone payment obligations for

pirfenidone related to the 2002 license agreement. The principal terms

of the new agreements were:

-- InterMune made total acquisition payments to the companies of $13.7

million. Of this total, a $7.5 million expense recorded in the

third quarter of 2007 relating to the 2002 license agreement was

applied to the acquisition payments for the new agreements. The

$6.2 million balance of the acquisition payments for the new

agreements was recorded in the fourth quarter of 2007.

-- Contingent acquisition payments associated with the new agreements

of up to an additional $53.5 million would be made by InterMune

only if positive Phase 3 data and registration in the United States

and European Union are achieved.

-- In addition, InterMune acquired exclusive worldwide rights from

Marnac to certain additional intellectual property for pirfenidone

that was not licensed under the 2002 licensing agreement, including

patents relating to the TNF-alpha activities of the compound.

-- ITMN-191: On January 7, 2008, InterMune reported the progress of its

Phase 1b multiple-ascending-dose (MAD) clinical trial evaluating

ITMN-191 (R7227) as monotherapy in patients with chronic hepatitis C

virus (HCV) infection. InterMune reported that:

-- It had completed the first two dosage cohorts in the study, with

total daily doses of up to 300mg, and that

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
(Date:10/9/2015)... ... ... Leading microbial genomics startup uBiome today launched the first-ever microbiome app, in ... and the microbiome. The study uses the ResearchKit framework, designed by Apple, to gather ... uBiome app is available as a free download from the App Store. The first ...
(Date:10/8/2015)... , Oct. 8, 2015  ATCC, the premier ... that it has been selected by The Michael J. ... cell lines to academic, pharmaceutical, and biotechnology organizations committed ... the United States , and more ... the United States , and more ...
(Date:10/8/2015)... Oct. 8, 2015 The 2015 Nobel Prize in ... of Texas at Dallas. Aziz Sancar , who earned ... Dallas in 1977, is one of three scientists who ... monitor and repair damaged DNA on a molecular level.  --> ... cell biology from UT Dallas in 1977, ...
(Date:10/8/2015)... , Oct. 8, 2015  Sigma-Aldrich Corporation (NASDAQ: ... ® brand within its Applied Diagnostics and ... acid reference standards product line with ten certified ... tested bile acids and their stable-labeled internal standards. ... of lithocholic acid, taurocholic acid and native and ...
Breaking Biology Technology:
... 1 ChromaDex, Inc. ("ChromaDex"),today announced that effective ... Acquisition, Inc. ("CDI"), the wholly-owned subsidiary of Cody,Resources, ... ChromaDex to be wholly owned by a company ... be better positioned to meet the ongoing needs,of ...
... Will Support Development of Bavituximab and Fully Human ... ... Peregrine,Pharmaceuticals, Inc. (Nasdaq: PPHM ), a clinical stage ... C virus (HCV) infection, today announced it has entered into ...
... July 1 Isis,Pharmaceuticals, Inc. (Nasdaq: ISIS ... $20 million in Ibis Biosciences, Inc., an Isis,subsidiary. ... the Ibis,T5000(TM) Biosensor System, which offers a unique ... By making this,investment, Abbott retains the exclusive option ...
Cached Biology Technology:
(Date:9/26/2015)... -- Results of a TactioRPM pilot project in a ... Stanford Medicine X Conference. In a presentation titled ... Devices and Pharmacogenomics", Roger Simard , Pharmacist ... senior patients equipped with connected health devices and ... TactioRPM remote patient monitoring platform were empowered to ...
(Date:9/10/2015)... , Sept. 10, 2015 This report ... wearable technology products today, and emerging sensor types that ... risen through the peak of the wearable technology hype ... slide to disillusionment. The common feature with all of ... key enabler for their most useful functions. Sensors collect ...
(Date:9/10/2015)... 2015 Pursuant Health has collaborated with ... an interactive, image-based health risk assessment (HRA) optimized ... The unique assessment quantifies user results into an ... an individual,s biological age based on personal health ... the kiosk. Comprised of age, gender, ...
Breaking Biology News(10 mins):
... of the brain, which scavenge pathogens and damaged neurons, are ... research by Duke neuroscientists. Earlier studies by Staci Bilbo, ... laboratory rats experiencing an infection at an early age have ... their learning and memory. In a study published ...
... Lake City Physicians preparing to deliver a baby look ... whether or not to perform a C- section. But a ... shows that those heart rate patterns may not be a ... lead to unnecessary interventions and higher costs. "We,re trying ...
... a class of theoretical concepts for manipulating the climate ... caused by greenhouse gasses. But its potential effectiveness and ... could help narrow these uncertainties. A team composed of ... and Harvard,s David Keith used modeling to determine the ...
Cached Biology News:
... for 25 chips provides the chips and ... (at picogram levels) with the Experion automated ... HighSens microfluidic chips, 2 x 1,250 microliters ... HighSens stain, 20 microliters RNA ladder, 2 ...
Vitronectin Immunogen: Purified, full length, native human protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
... StdSens analysis kit for 25 chips provides ... standard-sensitivity RNA analysis (at nanogram levels) with ... includes 25 RNA StdSens microfluidic chips, 2 ... 20 microliters RNA StdSens stain, 2 x ...
... White solid. PROTECT FROM LIGHT. PACKAGED UNDER ... pyrimidinone compound that acts as a potent ... (IC 50 = 200 nM and ... with little activity against the dehydrogenase activity ...
Biology Products: